|
|
||||||||
|
Abbott Laboratories, Abbott, IL
I would like to congratulate you on an excellent first edition of Molecular Interventions. This new journal really fills a void in the field of pharmacology. The blend of reviews and interviews makes for excellent reading.
I would offer one suggestion for fulfilling your hope to "earn the readership of every pharmacologist, whether in industry, academia, government, or elsewhere...." As chair-elect of ASPETs Division of Drug Discovery, Development, and Regulatory Affairs, I represent a significant number of industrial pharmacologists. As you are well aware, there has been some degree of separation between our academic and industrial colleagues in the past. One of the goals of the DDDRA is to ensure that the scientific interests of our industrial brethren are represented in ASPET meetings, publications, and functions. To that end, you might consider adding a person or two from industry to your editorial board. A diversity of input may broaden your impact with the entire membership of ASPET.
I look forward to the next issue!
Again, we really appreciate your interest in the journal, and we will take your suggestions very seriously.
Univ. Cincinnati, Coll. Med, Institute Molecular Pharmacology/Biophysics
I love the concept, and congratulations. The only drawback in the name of the new journal is that it will be forever known as "MI", and as an integrative pharmacologist, you know what that means! How does one become an integrative pharmacologist? Am I one? I feel the venture is an outstanding one and I wish ASPET all the very best of luck!!
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ASPET Journals | Pharmacological Reviews | Drug Metabolism and Disposition |
| Molecular Interventions | Molecular Pharmacology | J Pharmacology and Exp Therapeutics |